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Background: HD is an autosomal dominant neurodegenerative disease caused by CAG repeat expansion 
in the HTT gene resulting in polyglutamine expansion in the mutant huntingtin protein (mHTT) with a 
toxic gain-of-function disease mechanism.  No disease-modifying treatments are currently available.  In 
transgenic rodent models of HD, suppressing HTT production delays disease progression and reverses 
disease phenotype.  A drug discovery effort, including extensive preclinical testing, was undertaken to 
design a well-tolerated ASO with high specificity to human HTT mRNA that potently suppresses HTT 
production. 
Design/Methods: In this first-in-human, multi-center, double-blind clinical trial (NCT02519036), 46 
patients were randomized (3:1) to receive four doses of IONIS-HTTRx or placebo by monthly bolus 
intrathecal (IT) injection followed by a 4-month untreated period.  Five ascending-dose cohorts were 
enrolled with independent DSMB review of safety, PK and target engagement prior to dose escalation.   
Results: IONIS-HTTRx was well-tolerated at all doses tested.  Adverse events were mostly mild and 
unrelated to study drug.  There were no adverse trends in laboratory parameters.  No patients prematurely 
discontinued from treatment.  ASO was measurable in CSF and plasma. Significant, dose-dependent 
reductions in CSF mutant HTT (mHTT) were observed.   
Conclusions: ASO technology has the potential to provide disease-modifying benefits to patients with 
neurodegenerative diseases.  In this Phase 1/2a trial in early stage HD patients, IONIS-HTTRx delivered 
via IT injection was well tolerated with no study drug-related adverse safety signals during the treatment 
or follow-up periods.  Significant dose-dependent reductions in CSF mHTT were observed, suggesting 
that IONIS-HTTRx is a promising therapeutic for the treatment of HD. 
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